Evidence map›Paper›PMID 42266575›Full record

ArticleNAR genomics and bioinformatics2026

Exploring molecular signatures of senescence with marker, an R Toolkit for evaluating gene sets as phenotypic markers.

Rita Martins-Silva, Alexandre Kaizeler, Nuno L Barbosa-Morais

Abstract read
In one paragraph

Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rita Martins-SilvaGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035 Lisbon, Portugal.ORCID https://orcid.org/0000-0002-1067-7993
Alexandre KaizelerGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035 Lisbon, Portugal.ORCID https://orcid.org/0000-0002-9117-6073
Nuno L Barbosa-MoraisGIMM - Gulbenkian Institute for Molecular Medicine, 1649-035 Lisbon, Portugal.ORCID https://orcid.org/0000-0002-1215-0538

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many biological processes, including cellular senescence, manifest as diverse phenotypes across cell types and conditions. Lacking definitive markers, researchers often rely on the expression of sets of genes to identify these complex states. However, multiple approaches exist to summarize gene set expression into quantitative metrics (i.e. signatures), each with distinct strengths and limitations, and we know of no consensual framework to systematically evaluate their performance across datasets. We therefore developed markeR, an open-source, modular R package that evaluates gene sets as phenotypic markers using scoring and enrichment-based approaches. markeR generates interpretable metrics and intuitive visualizations for benchmarking gene signatures and exploring their associations with study variables. As a case study, we applied markeR to 9 published senescence-related gene sets across 25 RNA-seq datasets, 6 human cell types and 12 senescence-inducing conditions. Gene set performance varied widely: some signatures (e.g. SenMayo) were robust senescence markers across contexts, while others (e.g. MSigDB sets) performed poorly. We further applied markeR to 49 GTEx tissues, revealing tissue- and age-related differences in senescence-associated signals. Together, these findings emphasize the difficulty of characterizing molecular phenotypes and demonstrate markeR's potential for the systematic evaluation of gene sets in various biological contexts.

Indexed as

Cellular SenescenceSoftwareBiomarkersGene Expression ProfilingGenetic MarkersHumansPhenotypeBiomarkersGenetic Markers

Identifiers

PMID42266575
PMCPMC13244156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.